TY - JOUR
T1 - A paracrine circuit of IL-1β/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression
AU - Chen, Zhihong
AU - Giotti, Bruno
AU - Kaluzova, Milota
AU - Vallcorba, Montse Puigdelloses
AU - Rawat, Kavita
AU - Price, Gabrielle
AU - Herting, Cameron J.
AU - Pinero, Gonzalo
AU - Cristea, Simona
AU - Ross, James L.
AU - Ackley, James
AU - Maximov, Victor
AU - Szulzewsky, Frank
AU - Thomason, Wes
AU - Marquez-Ropero, Mar
AU - Angione, Angelo
AU - Nichols, Noah
AU - Tsankova, Nadejda M.
AU - Michor, Franziska
AU - Shayakhmetov, Dmitry M.
AU - Gutmann, David H.
AU - Tsankov, Alexander M.
AU - Hambardzumyan, Dolores
N1 - Publisher Copyright:
Copyright: © 2023, Chen et al.
PY - 2023/9/21
Y1 - 2023/9/21
N2 - Monocytes and monocyte-derived macrophages (MDMs) from blood circulation infiltrate glioblastoma (GBM) and promote growth. Here, we show that PDGFB-driven GBM cells induce the expression of the potent proinflammatory cytokine IL-1β in MDM, which engages IL-1R1 in tumor cells, activates the NF-κB pathway, and subsequently leads to induction of monocyte chemoattractant proteins (MCPs). Thus, a feedforward paracrine circuit of IL-1β/IL-1R1 between tumors and MDM creates an interdependence driving PDGFB-driven GBM progression. Genetic loss or locally antagonizing IL-1β/IL-1R1 leads to reduced MDM infiltration, diminished tumor growth, and reduced exhausted CD8+ T cells and thereby extends the survival of tumor-bearing mice. In contrast to IL-1β, IL-1α exhibits antitumor effects. Genetic deletion of Il1a/b is associated with decreased recruitment of lymphoid cells and loss-of-interferon signaling in various immune populations and subsets of malignant cells and is associated with decreased survival time of PDGFB-driven tumor-bearing mice. In contrast to PDGFB-driven GBM, Nf1-silenced tumors have a constitutively active NF-κB pathway, which drives the expression of MCPs to recruit monocytes into tumors. These results indicate local antagonism of IL-1β could be considered as an effective therapy specifically for proneural GBM.
AB - Monocytes and monocyte-derived macrophages (MDMs) from blood circulation infiltrate glioblastoma (GBM) and promote growth. Here, we show that PDGFB-driven GBM cells induce the expression of the potent proinflammatory cytokine IL-1β in MDM, which engages IL-1R1 in tumor cells, activates the NF-κB pathway, and subsequently leads to induction of monocyte chemoattractant proteins (MCPs). Thus, a feedforward paracrine circuit of IL-1β/IL-1R1 between tumors and MDM creates an interdependence driving PDGFB-driven GBM progression. Genetic loss or locally antagonizing IL-1β/IL-1R1 leads to reduced MDM infiltration, diminished tumor growth, and reduced exhausted CD8+ T cells and thereby extends the survival of tumor-bearing mice. In contrast to IL-1β, IL-1α exhibits antitumor effects. Genetic deletion of Il1a/b is associated with decreased recruitment of lymphoid cells and loss-of-interferon signaling in various immune populations and subsets of malignant cells and is associated with decreased survival time of PDGFB-driven tumor-bearing mice. In contrast to PDGFB-driven GBM, Nf1-silenced tumors have a constitutively active NF-κB pathway, which drives the expression of MCPs to recruit monocytes into tumors. These results indicate local antagonism of IL-1β could be considered as an effective therapy specifically for proneural GBM.
UR - http://www.scopus.com/inward/record.url?scp=85178495827&partnerID=8YFLogxK
U2 - 10.1172/JCI163802
DO - 10.1172/JCI163802
M3 - Article
C2 - 37733448
AN - SCOPUS:85178495827
SN - 0021-9738
VL - 133
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 22
M1 - e163802
ER -